Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight
The inflammatory bowel disease market is experiencing sustained growth, driven by the rising prevalence of Crohn's disease and ulcerative colitis, increasing disease awareness, and earlier diagnosis. Additionally, the launch of emerging therapies such as ABX464 (Abivax), Tulisokibart...
The inflammatory bowel disease market is experiencing sustained growth, driven by the rising prevalence of Crohn's disease and ulcerative colitis, increasing disease awareness, and earlier diagnosis. Additionally, the launch of emerging therapies such as ABX464 (Abivax), Tulisokibart...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.